Article Details

Morgan Stanley Upgrades Vir Biotechnology (NASDAQ:VIR) to “Overweight”

Retrieved on: 2025-01-11 18:41:55

Tags for this article:

Click the tags to see associated articles and topics

Morgan Stanley Upgrades Vir Biotechnology (NASDAQ:VIR) to “Overweight”. View article details on hiswai:

Excerpt

The brokerage presently has a $20.00 price target on the stock, up from their prior price target of $10.00. Morgan Stanley's target price points to a ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo